WEI WANG, MD/PHD
Osteopathic Medicine at Bellaire Blvd, Houston, TX

License number

Texas P7868

Professional information

Polymers Research Supervisor

Position:

R&D Supervisor at Total Petrochemicals & Refining USA, Inc., VP at Chinese American Chemical Society - Southwest

Location:

Houston, Texas Area

Industry:

Plastics

Work:

Total Petrochemicals & Refining USA, Inc. - La Porte, Texas since Jan 2012 - R&D Supervisor Chinese American Chemical Society - Southwest - Houston, Texas Area since Mar 2011 - VP Total Petrochemicals USA, Inc. - La Porte, Texas Oct 2009 - Dec 2011 - Senior R&D Chemist Total Petrochemicals USA, Inc. - La Porte, Texas 2007 - Sep 2009 - Analytical Science R&D Group Leader University of Houston - Houston, Texas Area 2007 - 2007 - Researcher

Education:

University of North Carolina at Chapel Hill 2001 - 2006
PhD, Chemistry Peking University 1997 - 2001
B.Sci., Chemistry

Skills:

GPC, HPLC, Polymer Characterization, Multivariate Statistics, Electrochemistry, Analytical Chemistry, Research Project Management, Industrial Safety

Interests:

Photography, Ice Skating, Sports Shooting, Golf

Languages:

Chinese

Environmental Engineer At Ch2M Hill

Position:

Environmental Engineer at CH2M HILL

Location:

Houston, Texas Area

Industry:

Environmental Services

Work:

CH2M HILL - Houston, Texas Area since Feb 2012 - Environmental Engineer Optimized Systems & Solutions - Houston, Texas Area Jan 2011 - Feb 2012 - Senior Implementation Consultant Air Quality Engineering Solutions, Inc. and University of Maryland Jul 2009 - Dec 2010 - Research Scientist Trinity Consultants - Greater Chicago Area May 2007 - Apr 2009 - Environmental Consultant University of Illinois at Urbana-Champaign - Urbana-Champaign, Illinois Area Aug 2002 - May 2007 - Research Assistant

Quantitative Research &Amp; Modeling

Location:

Houston, Texas Area

Industry:

Research

Work:

Webtrends, Inc. Jun 2009 - Sep 2010 - Analytical Research Intern (Part Time) Terex Corporation, Redmond, WA Jun 2007 - Sep 2007 - Summer Intern

Education:

University of Washington 2006 - 2011
University of Washington 2006 - 2007
MS, Industrial Engineering The Ohio State University 2004 - 2006
MS, Mathematics Nanjing University 2000 - 2004
BS, Computational Mathematics

Skills:

Algorithms, Monte Carlo Simulation, Machine Learning, VBA, SAS, Statistics

Sr. Principal Consultant At Aspentech

Position:

Sr. Principal Consultant at Aspentech

Location:

Houston, Texas Area

Industry:

Computer Software

Work:

Aspentech since Feb 2003 - Sr. Principal Consultant

Education:

East China University of Science and Technology 1987 - 1991
Master, Chemical Engineering

Wei (Wayne) Wang - Houston, TX

Work:

North Carolina State University - Raleigh, NC
Research Assistant Huazhong University of Science and Technology - Wuhan, China
Lab Assistant China Shipbuilding Industry Corporation - Wuhan, China
Industrial Intern

Education:

North Carolina State University - Raleigh, NC
MS in Coastal Engineering Huazhong University of Science and Technology - Wuhan, China
BS in Naval Architecture and Marine Engineering

Skills:

Matlab, AutoCAD, Microsoft Office, Wamit, GHS, GPU-SPH, ANSYS, Gambit, Fluent(CFD), ADCIRC, Techplot, ParaView, Fortran, C/C++, Python, HTML, Maple, Mathematica, Latex

Staff 2 At E&Amp;Y

Location:

Houston, Texas Area

Industry:

Accounting

Work:

Gerber Scientific Inc. Aug 2008 - Jun 2010 - Senior Audit Consultant E&Y Sep 2006 - Jul 2008 - Staff 2

Education:

Brigham Young University
Master, Accounting

Traceable Retinoid Acid For Imaging, Disease Prevention And Therapy

US Patent:

2012024, Sep 27, 2012

Filed:

May 6, 2010

Appl. No.:

13/319012

Inventors:

Shi Ke - Houston TX, US
Michel Mawad - Houston TX, US
Wei Wang - Houston TX, US

Assignee:

BAYLOR COLLEGE OF MEDICINE - Houston TX

International Classification:

C07D 403/08, A61K 49/04, A61K 49/00

US Classification:

424 944, 548455, 424 96, 424 91

Abstract:

The present invention provides nonradioactive NIR optical imaging agents based up on the structure of retinoid acid derivatives. The nonradioactive NIR optical imaging agent has been evaluated at the cellular level by confocal microscopy, and in vivo in a whole animal using a various xenograft models. The specific uptake of this agent in human cancer cells and multiple xenograft models demonstrate that nonradioactive near infrared dye labeled retinoid metabolites and/or analogs are useful for early stage cancer studies and diagnoses. Also, the present invention provides that nonradioactive near infrared dye labeled retinoid metabolites and/or analogs are useful for visualization of drug redistribution within the body which is useful in determining the optimal biological dose. Ultimately, the visualization data can be used as an analytical tool to reduce any systemic toxicity.

Non-Radioactive Agents For Neuroblastoma Imaging

US Patent:

2013022, Aug 29, 2013

Filed:

Apr 1, 2011

Appl. No.:

13/638060

Inventors:

Wei Wang - Houston TX, US
Jason Shohet - Houston TX, US
Michel Mawad - Houston TX, US
Shi Ke - Missouri City TX, US

Assignee:

Baylor College of Medicine - Houston TX

International Classification:

C07D 209/26

US Classification:

424 91, 548455

Abstract:

Multi-modal tumor imaging of neuroblastoma is essential for tumor staging, response evaluation and detection of relapsed diseased. The present invention provides a norepinephine analogue with a near-infrared (near-IR) dye, W765-BG, that efficiently and stably detects neuroblastoma in vivo using near-IR optical imaging. Confocal microscopy and optical imaging of neuroblastoma xenografts shows cell specific uptake and reveals exceptional tumor retention with a high tumor-to-tissue ratio up to 7 days after injection of W765-BG.